Interim analysis of promise, a clinical study combining the BET inhibitor OPN-2853 with ruxolitinib in patients with advanced myelofibrosis experiencing an inadequate response to ruxolitinib
Mead A., Psaila B., Boucher R., Wang J., Collings R., Record R., Nagy Z., Begum A., Knapper S., Wadelin F., Jain M., O'nions J., Mcmullin MF., Francis S., Harrington P., Narayanan S., Inokuchi K., Walling J., Huntley B., Harrison C.